Moderna said today that the protection of its vaccine against COVID-19 remained strong for at least six months and that the booster injection it is testing generated a “robust” antibody response against the delta variant. “We believe that a booster (dose 3) will probably be necessary this fall (in the northern hemisphere), particularly due to delta,” they specified from the laboratory that manufactures the doses that in our country began to be applied to minors between 12 and 17 years old. that fall within the risk group, and that were donated by the United States.
In a final analysis of its phase 3, or final phase, clinical trial, this laboratory’s covid vaccine was 93% effective six months after the second dose. The company is also conducting clinical trials with three different covid-19 boosters. All of them produce high levels of antibodies against the original strain of the coronavirus and the variants of interest, including the delta, originally identified in India and highly contagious.
“We are satisfied that our COVID-19 vaccine shows a long-lasting 93% efficacy at six months, but we recognize that the delta variant is a new and important threat, so we must remain vigilant,” said CEO Stephane. Bancel in a statement. And he adds that Moderna expects to submit a full approval request for its anticovid vaccine to the United States Food and Drug Administration (FDA) this month, since so far it is only authorized for emergency use.
The company has also started studies for other vaccines, such as influenza, Zika and respiratory syncytial virus, among others, and is developing a covid vaccine that can be stored at refrigerator temperature.
On the other hand, the American pharmaceutical company warned that a third dose of its anti-covid vaccine will be necessary before the end of the year due to the probable increase in infections caused by the delta variant. In the investor presentation related to its quarterly results, Moderna also revealed its latest data and strategy regarding the third booster dose, on which it is studying the most effective amount of product.
“We believe that a booster (dose 3) will probably be necessary this fall (northern hemisphere), particularly due to delta,” said the company, which has obtained promising protection data with a dose of 50 micrograms and expects that of another dose of 100 Moderna opined that “increased infection strength resulting from delta,” “fatigue” from prevention actions, and “seasonal effects,” such as spending more time indoors, “will lead to an increase in breakthrough infections in vaccinated people.” .
According to the document, the firm has expectations that the 93% efficacy against COVID-19 infections that has been proven after the two-dose regimen will begin to “decline” after six months “and eventually impact” those results. . “Given this intersection, we believe that a third booster dose will likely be necessary before winter (from the northern hemisphere),” he insisted.
Moderna is still studying that third booster dose, which was offered with a 50 microgram amount of product to a group of patients six months after receiving the second dose. The truth is that the third dose “boosted” their antibody levels to exceed the efficacy obtained in the original clinical trial of the vaccine, and also in a “similar” way between different age groups, especially in adults over 65 years of age.
On the other hand, Moderna today disclosed earnings of 4,001 million dollars through June, with which it achieves the first six-month net profit in its history, thanks to the sales of its vaccine against covid-19, for which it received 5,900 million Dollars.